(NASDAQ: KYMR) Kymera Therapeutics's forecast annual revenue growth rate of -0.1% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.26%.
Kymera Therapeutics's revenue in 2025 is $58,885,000.On average, 11 Wall Street analysts forecast KYMR's revenue for 2025 to be $5,469,457,636, with the lowest KYMR revenue forecast at $1,439,142,453, and the highest KYMR revenue forecast at $14,651,902,800. On average, 11 Wall Street analysts forecast KYMR's revenue for 2026 to be $3,643,374,710, with the lowest KYMR revenue forecast at $1,302,391,360, and the highest KYMR revenue forecast at $9,767,935,200.
In 2027, KYMR is forecast to generate $4,453,787,734 in revenue, with the lowest revenue forecast at $2,604,782,720 and the highest revenue forecast at $9,442,337,360.